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Acetylcholinesterase (AChE) is an enzyme that catalyzes the conversion of the neurotransmitter 
acetylcholine (ACh) into acetate and choline. ACh binds to muscarinic and nicotinic 
acetylcholine receptors triggering muscle contraction or neuronal communication. 
Organophosphorus (OP) nerve agents and pesticides inhibit and/or age the active site of AChE. 
AChE inhibition is the process by which the OP compound forms a covalent bond with the active 
site serine, whereas aging is the dealkylation of the OP moiety in the OP-AChE complex after 
inhibition. After inhibition and/or aging of AChE, a buildup of ACh in the synaptic clefts and 
neuromuscular junctions occurs, an event known as a cholinergic crisis, which causes severe 
harm and even death to an untreated individual. Currently approved therapeutics reactivate 
inhibited AChE, but they do not resurrect, or return to normal function, the aged form of the 
enzyme. Additionally, these positively charged therapeutics are incapable of crossing the blood-
brain barrier, which is impermeable to charged molecules. Therefore, novel therapeutics must be 
developed to improve the treatment of OP poisoning. One approach to reducing the severity of 
OP poisoning is through the use of positive allosteric modulators of AChE. In general, a positive 
allosteric modulator (PAM) binds to an enzyme at a location removed from the active site and 
modifies the enzyme in a manner that increases its catalytic rate. Utilizing PAMs of AChE would 
enable remaining native AChE to increase the rate of conversion from ACh to acetate and 
choline, reducing the amount of AChE required to prevent cholinergic crisis. The modification of 
AChE caused by PAMs might also prevent OP agents from reacting with the active site serine or 
slow the rate of reaction. Further, the modifications caused by PAMs could potentially enhance 
the reactivation and/or resurrection of inhibited or aged AChE. Therefore, the initial goal of this 
project was to 1) identify novel PAMs of AChE, 2) test the identified compounds for 
prophylactic capabilities, and 3) identify which PAMs enhance the rate of reactivation and/or 
resurrection of AChE. However, a number of obstacles were encountered that question the 
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Role of Acetylcholine in the Body 
Acetylcholine, the first neurotransmitter to be discovered (Meriney & Fanselow, 2019), is 
found in the autonomic, somatic, and central nervous systems where it is synthesized by 
presynaptic neurons (Figure 1).  
Figure 1: Synthesis of Acetylcholine - Choline acetyltransferase (ChAT) combines choline and acetyl-CoA to form 
acetylcholine. Acetylcholine (ACh) is then stored in vesicles that merge with the synaptic membrane to release ACh into the 
synapse. Acetylcholinesterase (AChE) hydrolyzes ACh into acetate and choline. High-affinity, low-efficiency choline uptake 
transporters (HACU) transport the resulting choline back into the presynaptic neuron. (Meriney & Fanselow, 2019) 
In the central nervous system, acetylcholine is synthesized in the basal forebrain nuclei and the 
mesopontine tegmental area of the brain. Although the role of acetylcholine in the brain is not 
fully understood, it is thought to play a role in arousal, attention, and memory. However, in the 
rest of the body, acetylcholine serves to induce muscle contraction in the neuromuscular 
junctions by triggering the uptake of sodium into the muscle cell and releasing potassium. Two 
acetylcholine receptors are important in the neurotransmitter activity: muscarinic and nicotinic 
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receptors. The names of these receptors originate from the chemicals they bind in addition to 
acetylcholine. Muscarinic receptors bind muscarine, and nicotinic receptors bind nicotine 
(Figure 2).  
 
Figure 2: Structures of Acetylcholine receptor agonists 
To control the activation of acetylcholine receptors, the acetylcholinesterase (AChE) enzyme 
catalyzes the conversion of ACh into acetate and choline (Figure 1; Figure 3).  
Structure of Acetylcholinesterase 
AChE exists in many isoforms depending on the species (human, mouse, eel, etc.) and 
where it is located in the body (synaptic cleft, neuromuscular junction, erythrocyte, etc.). 
Globular AChE can exist as a monomer, dimer, or tetramer (Sakayanathan et al., 2019). One 
common characteristic of an AChE subunit is the narrow gorge that is 0.75 to 2.5 angstroms 
Figure 3: AChE hydrolysis of ACh (Franjesevic et al., 2019) 
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wide and 20 angstroms deep (Franjesevic et al., 2019; Figure 4). The mouth of the gorge 
is home to the peripheral anionic site (PAS) that interacts with the choline segment of ACh to 
thrust the substrate into the catalytic site.  
Inhibition of AChE has been shown to be a therapeutic approach for treating symptoms 
of certain illnesses such as Alzheimer’s Disease (AD) and myasthenia gravis. Donepezil, 
rivastigmine, and galantamine treat AD, whereas pyridostigmine bromide treats myasthenia 
gravis. Unfortunately, AChE is also the target of many organophosphorus nerve agents and 
pesticides.  
Organophosphorus Nerve Agents and Pesticides 
Since Gerhard Schrader stumbled upon tabun while developing insecticides in 1936, 
many nations have pursued organophosphorus nerve agents as part of their chemical weapons 
programs (Franjesevic et al., 2019).  Germany developed tabun (GA), sarin (GB), soman (GD), 
and cyclosarin (GF); the United States developed VX; and Russia developed VR and several 
Novichok agents (Figure 5).  





Figure 5: Structures of OP Nerve Agents - G-series (Top), V-series (Middle), and Novichok Agents (Bottom) 
Of course, these chemicals have not remained isolated in the countries where they were 
developed. For example, in the 1980s, Iraq used hundreds of tons of sarin and tabun against 
Iranian troops affecting over 100,000 people (Franjesevic et al., 2019). In 2013 and 2017, the 
Syrian government used sarin on rebel forces, killing and injuring close to 2,000 people between 
the two incidents (Franjesevic et al., 2019).  Even more recently, Russia has been under scrutiny 
by the United Nations for utilizing Novichok agents to carry out assassinations, or assassination 
attempts, like that on President Vladmir Putin’s political rival Alexei Navalny (“Russia 
responsible,” 2021).  
Outside of the militarization of nerve agents, they have also become a powerful tool for 
terrorist organizations. The danger of these agents in the hands of terrorists can be seen in the 
Matsumoto attack of 1994 and the Tokyo subway attack of 1995 (Gupta, 2020). On June 27, 
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1994, sarin gas was dispersed in Matsumoto City, Japan killing eight people and hospitalizing 
many others. Following this attack, in 1995, a cult released homemade liquid sarin on a subway 
killing 13 people and hospitalizing over 5000. However, had the sarin been in the gas phase like 
the Matsumoto attack, it is likely the death toll would have been much higher (Franjesevic et al., 
2019).  
In agriculture, organophosphorus pesticides have been popular for protecting crops 
despite the known risks associated with their use. As of 2012, approximately one third of all 
insecticides used annually in the United States were organophosphorus compounds (Atwood & 
Paisley-Jones, 2017). Examples of these pesticides include acephate, chlorpyrifos, diazinon, 
malathion, and parathion (Figure 6).  
 




Organophosphorus Poisoning and Treatment 
Poisoning by organophosphorus nerve agents or pesticides results in a variety of severe 
symptoms, some of which comprise the mnemonic SLUDGE: salivation, lacrimation, urination, 
defecation, gastric cramps, and emesis (Peter et al., 2014). However, a more comprehensive 
mnemonic device for the symptom of OP poisoning is BAG the PUDDLES (Figure 7).  
The mechanism by which organophosphorus nerve agents and pesticides elicit these 
symptoms is through their reaction with AChE and involves two steps. The first step involves the 
formation of a covalent bond with the active site serine forming inhibited AChE (Figure 8). The 
Figure 7: Mnemonic device for symptoms of OP poisoning (Gupta, 2015)
 
Figure 8: Mechanism of OP Inhibition and Aging (Franjesevic et al., 2019) 
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second is an enzyme-catalyzed dealkylation of the organophosphorus moiety of the OP-AChE 
complex which is known as aging.  
In both inhibited and aged AChE, the enzyme can no longer convert ACh to acetate and 
choline. This results in a buildup of the neurotransmitter in the synaptic cleft or neuromuscular 
junction leading to a cholinergic crisis where the excess of ACh leads to an increased rate of 
binding and activation of the acetylcholine receptors. 
To treat the resulting symptoms, atropine, diazepam, and an AChE reactivator are given 
to the poisoned patient. Atropine acts as a competitive antagonist of muscarinic ACh receptors, 
reducing the activation of these receptors by the excess of ACh (Rotenberg & Newmark, 2003). 
Diazepam is a benzodiazepine that serves to allosterically enhance binding of the inhibitory 
neurotransmitter GABA to GABAA receptors, thereby reducing or preventing seizures resulting 
from the cholinergic crisis. Since neither atropine nor diazepam restore the native function of 
AChE, reactivators such as 2-PAM, which is approved for use in the United States, HI-6, or 
obidoxime are administered to restore the native function of AChE from the OP-inhibited state. 
Unfortunately, there are no currently approved therapeutics that resurrect aged AChE or 
sufficiently cross the blood-brain barrier to restore brain AChE function. Although resurrecting 
AChE has proven to be more difficult, there have been leads in developing resurrectors that 





The currently approved treatment options for OP poisoning are primarily post-exposure 
therapeutics. The clear downsides to these approaches are that the patient still endures severe 
symptoms prior to treatment with a reactivator and/or endures long-lasting effects from the OP 
agents if there is significant absorption of the OP into the brain (Gupta, 2020). An alternative 
approach would be through a prophylactic, pre-exposure treatment that would prevent or limit 
the severe symptoms a patient would experience. While they are more likely to be effective post-
exposure, one such approach could be through the use of positive allosteric modulators of AChE. 
In general, a positive allosteric modulator (PAM) binds to an enzyme away from the active site 
and modifies the enzyme in a manner that increases its catalytic rate. The catalytic rate (kcat) of 
native AChE is approximately 25,000 molecules of ACh per second with a catalytic efficiency 
(kcat/KM) of 1.50×10
9 M-1 s-1 (Colovic et al., 2013). With such a high efficiency, it is reasonable 
for the PAM approach to be met with skepticism. However, there have been a number of studies 
suggesting that the rate of ACh hydrolysis can be increased while maintaining the KM, thereby 
increasing the efficiency of the enzyme (Reiner & Simeon-Rudolf, 2000; Grifman et al., 1997; 
Alvarez et al., 1998). Further, a number of allosteric binding sites have been identified through 
computational approaches (Roca et al., 2018). This potential for PAMs to bind to AChE and 
increase the rate of hydrolysis of ACh provides an obvious avenue for treatment. If PAMs are 
administered post-exposure, the remaining native AChE would have an increase in the rate of 
conversion of ACh, reducing the amount of AChE required to prevent the cholinergic crisis. If 
the effective activity of AChE is increased above 20%, then the patient would no longer 
experience severe symptoms (Colovic et al., 2013). As the percent of effective AChE activity 
increases, the patient’s symptoms in theory would reduce even more. This approach has the 
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potential to be extremely effective when combined with the current standard of care for OP 
poisoning, especially considering the reactivation abilities of 2-PAM and HI-6 (Franjesevic et 
al., 2019). Provided the PAMs can cross the blood-brain barrier, then the effective activity of 
brain AChE could also be increased, protecting the central nervous system. However, if PAMs 
modify AChE causing an increase in the rate of hydrolysis of ACh, they may also affect the 
inhibition rate by OPs, potentially reducing the rate of inhibition. Reducing the inhibition rate of 
AChE by OPs could provide a pre-exposure prophylactic for soldiers who may come in contact 
with an OP nerve agent or agriculture workers who may come into contact with higher 
concentrations of OP pesticides, protecting individuals against severe symptoms and even death 
after exposure. Prochlorperazine, an FDA-approved antipsychotic, was demonstrated to have this 
capability in vitro but there are no PAMs that have been shown to have this effect in humans yet 
(Katz et al., 2018). Additionally, even if given post-exposure, if the rate of inhibition by OPs is 
reduced, PAMs would protect the remaining uninhibited enzyme from becoming inhibited. 
Another potential benefit of this treatment approach is that the modification of AChE caused by 
PAMs might prevent OP metabolites, whether from normal processes or reactivation of AChE, 
from interacting with the active site serine. Further, the modifications could also enhance the 
reactivation and/or resurrection of inhibited or aged AChE either through rate enhancement or 
increasing the uptake of the therapeutic compound to the active site. Therefore, the purpose of 
this project was to utilize a modified Ellman’s method in vitro to 1) identify novel PAMs of 
AChE through a dose-response assay, 2) test the identified compounds for prophylactic 
capabilities via a protection assay, and 3) identify which PAMs enhance the rate of reactivation 
and/or resurrection of AChE by their respective assays. Unfortunately, a number of issues were 
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Materials and Methods 
Enzyme 
The AChE used in these experiments was generously provided by Dr. Zoran Radic from 
the University of California San Diego. It is a recombinant human isoform of the enzyme 
consisting of only the catalytic core expressed in HEK293 cells. 
Compound Library 
A library consisting of several sets of compounds were purchased to develop a structure-activity 
relationship (SAR). The first set was purchased from Enamine and consisted of 27 compounds 
(Figure 9). This set was planned around compounds (in red) that had previously been shown to 
activate AChE. Specifically, these compounds were identified by the high-throughput screening 
during the Chapleau et al. (2015) experiments and demonstrated a dose-response PAM activity. 







Figure 9: Compounds based on Chapleau et al. pharmacophores (red) 
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The second set was provided by Dr. Craig McElroy and consisted of compounds also from the 
Chapleau et al. (2015) experiments (Figure 10).  
 
Figure 10: Compounds from the Chapleau et al. (2015) experiments 
Prior to this A3 was resynthesized following a similar method which is detailed below. The A 
compounds were verified by NMR to have a purity above 95%, thanks to Garima Agarwal prior 
to use (data not shown). The last set was purchased based on the results of Katz et al. (2018; 
Figure 11). These compounds are all currently FDA-approved drugs and could provide an 
interesting lead in the development of another treatment against OP poisoning.  
 
Figure 11: FDA-approved drugs that showed activation in Katz et al. (2018) 
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Synthesis of A3 
After preparing 100 mM borate buffer at pH 9, 1.98 grams of p-aminophenol was 
dissolved while stirring for 20-30 minutes at room temperature. 2.01 grams of potassium 
ferricyanide was added and the reaction mixture turned black in color. Air was then bubbled 
through the reaction mixture at room temperature while being stirred until it was dry. The 
resulting black solid was filtered and washed with water before triturating into methanol. After 
evaporating the methanol, purified black A3 remained (1.28 g, 66%).  
 
Scheme 1: Synthesis of A3 from para-aminophenol 
Solvation of Test Compounds 
Solvation of the test compounds for testing proved difficult and a large number of 
solvents were used in trying to dissolve compounds 1-27 to a concentration of 100 mM so that 
the final concentration of solvent in the assay was as low as possible. These solvents are listed 
below (Table 1).  
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An attempt was made to avoid or reduce the amount of dimethylsulfoxide (DMSO) used for 
solvation as it causes a decrease in AChE activity. Therefore, in addition to the individual 
solvents, a few binary solvent mixtures were also prepared by combining DMSO and acetone 
which does not demonstrate as much inhibition (Kumar & Darreh-Shori, 2017). Each attempt at 
dissolving the compounds consisted of vortexing the vials at 2500 rpm for an hour on a 
Benchmark BV1010 Multi-tube Vortexer. Although the vials were not placed in an incubator, 
the friction generated on the vortexer surprisingly led to a significant amount of heat. If the 
compounds did not dissolve, the solvent was evaporated on an Organomation MULTIVAP100 
Nitrogen Evaporator or in a Genevac EZ-2 PLUS. If DMSO was a component of the solvent, the 
remaining DMSO was lyophilized using a Labconco Freezone 6 Lyophilizer. Unfortunately, 
only compounds 5, 6, 10, 17, and 23 dissolved at 100 mM in the binary solvent mixture 
solutions. The remaining compounds were not soluble enough to form 100 mM solutions in any 
of the solvents listed with some compounds appearing to be completely insoluble in all of the 
solvents. In fact, most were only soluble at 10 mM in DMSO. Eventually, to maintain 
uniformity, all compounds tested were dissolved at 10 mM in DMSO, including 5, 6, 10, 17, and 
















A variety of dose-response assays were performed while attempting to determine the 
activation potencies of the test compounds. Each assay was modified slightly from the previous 
one in order to address the obstacles that are discussed below. In all of these assays, the final 
concentrations of acetylthiocholine (ATC) and 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) were 
0.5 mM and 1 mM, respectively. If bovine serum albumin (BSA) was added, its final 
concentration was 0.09 g/L. ATC was prepared in water, DTNB was prepared in 20 mM 
Na3PO4, and BSA was prepared in 200 mM sodium phosphate buffer at pH 7.5. Each assay also 
utilized 200 mM sodium phosphate buffer at pH 7.5 unless otherwise noted. The addition of 
ATC and DTNB was performed using the dispensing module on a Biotek Synergy H1 Hybrid 
plate reader followed by a 20-second linear shake prior to a sweep read at 412 nm. All other 
assay components were added using an Integra Assist Plus robotic liquid handler equipped with 
Integra Voyager pipettes and Low Retention pipette tips. AChE, BSA, ATC, and DTNB 
solutions were mixed on a Thermolyne RotoMix Single Speed Orbital Mixer for approximately 
30 minutes before being used. AChE and BSA solutions were kept on ice during this time. ATC 
and DTNB solutions were vortexed for several minutes before being placed on the mixer. 
Solvent Dose-Response 
While attempting to dissolve the test compounds, the solvents with an unknown effect on 
AChE or the other assay materials were tested to determine their compatibility with the assay. 
Benzylamine, cyclohexanone, pyridine, and triethylamine were added so that their final 
concentrations (% v/v) were 10, 5, 2.5, and 1%.  Phosphate buffer, distilled water, acetonitrile, 
and DMSO were included as controls. Each well contained AChE and BSA in phosphate buffer 
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before the test solvents were added. ATC and DTNB were then added using the dispensing 
module on the plate reader. 
Compound Dose-Response 
As noted above, a variety of dose-response assays were performed. Brief descriptions of 
each assay will be detailed here with a summary table at the end of this section (Table 2).  
The first assay was performed by serially diluting the 100 mM stock solutions of 
compounds 5, 6, 10, 17, and 23 into 200 mM sodium phosphate buffer on a PCR plate with 2 
mM as the highest concentration in the dilution series. Despite sufficient mixing, a precipitate 
formed in the initial wells upon the addition of the test compound solutions, including the 3:1 
acetone-DMSO negative control.  
The second assay utilized a direct, variable volume dilution method where three different 
volumes of 100 mM compound were dispensed into separate wells of 200 mM sodium phosphate 
buffer to achieve final concentrations of 1.00, 0.50 and 0.25 mM. These wells were then serially 
diluted five-fold into 200 mM sodium phosphate buffer. A negative control with a 3:1 acetone-
DMSO solution was prepared in parallel. This assay also could not be completed due to the 
formation of precipitates in the dilution plate.  
The third assay consisted of adding the AChE and BSA components to the 200 mM 
sodium phosphate buffer prior to three direct, variable volume dilutions of compounds 5, 6, 10, 
17, 19, 20, and 23 at 10 mM in DMSO resulting in wells with final concentrations of 0.25, 0.10, 
and 0.05 mM. Each variable volume dilution was followed by a 10-fold serial dilution. The final 
relative activity of AChE was 0.0017 umol/min in each well. After incubating the plate at 37°C 
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for 30 minutes, ATC and DTNB were added and a sweeping, 10-minute kinetic read was 
performed at 412 nm. 
Because the results of the third assay did not match those in the literature, the fourth 
assay took note of the method of Chapleau et al. (2015) where the test compounds were added by 
an Echo 550 liquid handler. To mimic this, small droplets of 10 mM compound in DMSO were 
added to empty wells before a pre-mixed solution of AChE and BSA in 200 mM sodium 
phosphate buffer was slowly added so that the relative activity of AChE was the same in each 
well. The wells were vigorously mixed before a five-fold dilution was performed. After 
incubating the plate at 37°C for 30 minutes, ATC and DTNB were added and a sweeping, 10-
minute kinetic read was performed at 412 nm. 
The fifth assay was a modification of the fourth assay. The incubation time was increased 
to 1 hour, and the concentration of AChE was reduced so that the relative activity in each well 
was 0.0004 umol/min. Additionally, the number of direct, variable volume dilutions was 
decreased to two yielding concentrations of 50 uM and 25 uM. These wells were then serially 
diluted five-fold. Lastly, the contents of the 96-well plate were transferred to a 384-well format 
after incubation. The 384-well plate was then placed on the plate reader, and the 96-well plate 
was returned to the incubator while the 384-well plate was read. After another hour had passed, 
the 96-well plate was then read.  
The sixth assay was a repeat of the fifth assay. However, instead of 200 mM phosphate 




The seventh assay was also similar to the fifth assay. Again, only the one-hour incubation 
was performed, and the final concentration was slightly greater yielding an activity of 0.0006 
umol/min in each well.  
After noticing the lower concentrations were still resulting in AChE activity similar to the 
negative DMSO control, the plate layout from the fifth through seventh assays was modified for 
the eighth assay to double the number of compounds tested per run using only the five greatest 
concentrations from the previous assays, starting with 50 uM. The AChE concentration was also 
lowered to yield a final activity of 0.0003 umol/min in each well.  
Due to shipping delays, the 300 uL tips for the Integra Voyager were depleted during the 
course of the experiments so the 1250 uL pipette was used to dispense the appropriate volumes 
for the ninth through eleventh assays. The ninth assay was similar to the eighth assay, but the 
concentration of AChE was increased to yield an activity of 0.0021 umol/min in each well. 
After acknowledging BSA was not included in either the Chapleau et al. (2015) or Katz 
et al. (2018) experiments, the tenth assay was a repeat of the ninth assay but excluded BSA to 
investigate the effect of BSA on the test compounds.  
For the eleventh assay, AChE was incubated overnight (~13 hours) at 37°C in 200 mM 
sodium citrate buffer pH 6.0 to denature some of the enzyme. The activity of the incubated 
AChE was then tested with a non-incubated sample for comparison. The tenth assay procedure, 









In addition to performing multiple dilution series, two single-point high concentration 
assays were also performed using the modified Ellman’s method. The first was at a final 
compound concentration of 250 uM in each well, resulting in a final DMSO concentration of 
2.5% in phosphate buffer with AChE, before the addition of ATC and DTNB. No BSA was 
added to follow the methods of Chapleau et al. (2015) and Katz et al. (2018). To account for the 
inhibitory effect of DMSO on AChE, the inhibition curve of DMSO was used to calculate the 
amount of AChE needed to have a final relative activity of 0.002 units. The second assay was 
performed similarly with a final compound concentration of 125 uM in each well resulting in a 
final DMSO concentration of 1.25% in phosphate buffer with AChE, before the addition of ATC 
and DTNB. 
Data Analysis 
All calculations were performed using the linear slope of the absorbance data obtained by 
the plate reader. Each slope had a coefficient of determination (R2) value of 0.985 or greater 
unless the slope was significantly small. The outliers of the positive controls were then removed 
using the GraphPad outlier calculator (https://www.graphpad.com/quickcalcs/grubbs1/). The 
slopes from wells including either test compounds or the DMSO negative control were divided 
by the average of the positive control (either with BSA or without BSA) to determine the percent 
relative activity. These data were then transferred to GraphPad Prism 8 where experimental 
outliers were removed and the data were fit using a dose-response three- or four-parameter 






The solvent dose-response assay showed significant precipitation (Figure 12). The wells 
containing pyridine showed the most precipitation followed by benzylamine. Triethylamine and 
cyclohexanone wells showed the least precipitation. The precipitates in pyridine and 
benzylamine wells developed in a bead formation at the bottom of the wells. The precipitates in 
the triethylamine and cyclohexanone wells essentially formed an opposite pattern, where the 
precipitate formed a ring around the outer edge of the well but not in the center where the solvent 
was added. The control wells, where an equal amount of phosphate buffer, distilled water, 
acetonitrile, or DMSO was added, did not show precipitation. Because of the significant amount 
of precipitation with the four solvents of interest, the activity data are not included.  





As mentioned above, precipitation occurred during the first assay after the initial dilution 
despite sufficient mixing. Further, a precipitate was observed in the 3:1 acetone-DMSO negative 
control. Precipitation was also observed in all of the wells in the second assay including the 3:1 
acetone-DMSO control. 
Precipitation was absent in the third assay. However, only compounds 5 and 20 showed 
activity greater than the DMSO control (Figure 13). Compound 17 showed inhibition greater 
than that of DMSO. The activity data associated with compounds 6, 10, 19, and 23 all converge 
on the DMSO data at the higher concentrations. The average activity of the positive control was 
0.0017 umol/min with a coefficient of variation (CV) of 4%. 
 
The results of the fourth assay were similar to the third assay. No precipitation was 
observed and only compounds 5 and 20 demonstrated activity greater than the DMSO control at 
Figure 13: Results from the third assay 
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the highest concentration (Figure 14). However, compounds 20 and 23 showed activity greater 
than the DMSO control at 10 uM. Compounds 17 and 19 showed similar inhibition of AChE. 
Compounds 6 and 10 showed activity in between DMSO and compounds 17 and 19. The average 
activity of the positive control was 0.0017 umol/min with a CV of 2%. 
For the fifth assay, the A compounds demonstrated AChE inhibition greater than DMSO 
after the one-hour incubation (Figure 15). Both samples of A4 showed almost complete 
Figure 14: Results from the fourth assay 
Figure 15: Results from the fifth assay (1-hour incubation) 
26 
 
inhibition at higher concentrations. A3 and A5 showed similar inhibition between the A4 
samples and DMSO. Compound 17 demonstrated a higher potency than the A4 samples but did 
not achieve the same maximal inhibition. Compound 20 was similar to DMSO in this assay. The 
data after the two-hour incubation showed similar trends to the one-hour incubation (Figure 16). 
The average activity of the positive controls after the one-hour and two-hour incubation were 
both 0.0004 umol/min with a CV value of 5% for the one-hour incubation and a CV value of 4% 
for the two-hour incubation.  
The results of the sixth assay are nearly identical to the fifth assay (Figure 17). The 
average activity of the positive control for the sixth assay was 0.0004 umol/min with a CV of 
2%. 
 
Figure 16: Results from the fifth assay (2-hour incubation) 
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For the seventh assay, compounds 16, 19, 21, and 25 demonstrated large increases in 
inhibition of AChE compared to DMSO (Figures 18-21). Compounds 1, 2, 3, 4, 6, 8, 10, 11, 15, 
18, 22, 24, 26, 27 showed modest increases in inhibition compared to DMSO. The data for 
compounds 5, 7, 9, 12, 13, 14, and 23, as well as A5 and 2-PAM, were similar to the DMSO 
control. The concentration of AChE in all four plates associated with the seventh assay yielded 
an activity of 0.0006 umol/min and CVs between 3% and 7%. 
Figure 17: Results from the sixth assay 






Figure 19: Results from the seventh assay (Part 2) 
Figure 20: Results from the seventh assay (part 3) 
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For the eighth assay, compounds 11, 15, 16, 17, 19, 22, 24, 25, and 27 demonstrated large 
increases in inhibition of AChE compared to DMSO (Figures 22-25). Compounds 1, 2, 3, 4, 6, 
7, 9, 23, 26, A3 (12-20), and A5 showed modest increases in inhibition compared to DMSO. The 
data for compounds 10, 12, 13, and 14 were similar to the DMSO control. There was a large 
amount of variation for compound 8, and compound 18 lacked a clear trend. The concentration 
of AChE in both sets of corresponding positive controls yielded an activity of 0.0003 umol/min 
with CVs of 5% for plate 1 and 2% for plate 2. 
Figure 21: Results from the seventh assay (part 4) 






Figure 21: Results from the eighth assay (part 2) 
Figure 22: Results from the eighth assay (part 3) 
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For the ninth assay, compounds 16, 17, 19, and 21, as well as A4 (2/16), demonstrated 
large increases in inhibition of AChE compared to DMSO (Figures 26-29). Compounds 1, 6, 7, 
8, 11, 15, 18, 20, and 26, as well as 2-PAM, doxepin, imipramine, chlorpromazine, 
trifluoperazine, and A3 (12/20), showed modest increases in inhibition compared to DMSO. The 
data for compounds 2, 3, 4, 5, 9, 12, 13, and 14 were similar to the DMSO control. There was a 
large amount of variation for compounds 10 and A5 in addition to all four sets of DMSO 
controls. The concentration of AChE in both sets of corresponding positive controls yielded an 
activity of 0.0021 umol/min with CVs of 30% for plate 1 and 29% for plate 2. 
Figure 23: Results from the eighth assay (part 4) 





Figure 26: Results from the ninth assay (part 2) 
Figure 25: Results from the ninth assay (part 3) 
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For the tenth assay, compounds 16 and 21 demonstrated large increases in inhibition of 
AChE compared to DMSO (Figures 30-31). Compounds 7 and 8, along with A3 (12/20) and A4 
(N.D.), showed modest increases in inhibition compared to DMSO. The data for compounds 20, 
26, A5, doxepin, imipramine, chlorpromazine, trifluoperazine, amitriptyline, and 
prochlorperazine were similar to the DMSO control. However, there was a large amount of 
variation associated with this assay. The concentration of AChE in the positive control including 
Figure 28: Results from the ninth assay (part 4) 
Figure 27: Results from the tenth assay (part 1) 
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BSA yielded an average activity of 0.0016 umol/min with a CV of 44%, whereas the positive 
control excluding BSA yielded an average activity of 0.0021 umol/min with a CV of 20%. 
Prior to the eleventh assay, the AChE stock solution stored in the fridge and the AChE 
incubated overnight showed over a 15-fold difference in activity with the former determined to 
have an average activity of 0.0114 umol/min and a CV of 26%, and the latter having an activity 
of 0.0007 umol/min with a CV value of 9%. The incubated AChE stock was then used for the 
eleventh assay. In the assay, compounds 7, 8, 16, 20, 21, and 26, as well as doxepin, imipramine, 
chlorpromazine, trifluoperazine, amitriptyline, A3 (12/20), A4 (N.D.), and A5 demonstrated 
inhibition of AChE greater than that of DMSO (Figures 32-33). Prochlorperazine showed an 
increase in activity at the highest concentration above the DMSO control but was within one 
standard deviation of the DMSO control. However, there was a large amount of variation 
associated with this assay. The concentration of AChE in the positive control including BSA 
Figure 29: Results from the tenth assay (part 2) 
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yielded an average activity of 0.0016 umol/min with a CV of 44%, whereas the positive control 
excluding BSA yielded an average activity of 0.0021 umol/min with a CV of 20%. 
 
 
Figure 30: Results from the 11th assay (part 1) 




For the single-point assays, several compounds showed greater activity than the DMSO 
control. 2-PAM, compound 20, A5, and A4 (2/16) showed the greatest increases for the 125-uM 
experiment (Figure 34). For the 250-uM experiment, only compounds 13 and 20 yielded activity 
above the DMSO control average with both being within one standard deviation of the DMSO 
average (Figure 35). However, precipitation was observed in most of the wells from both 
experiments including the wells with compounds 13, 20, A4 (2/16), and A5 (Figure 36). The 
activities of AChE in the positive controls for the 125-uM and 250-uM experiments were 0.0405 
umol/min and 0.0415 umol/min, respectively. 
  



















Figure 34: Precipitation (top) and plate map (bottom) from single-point assays with the 250-uM experiment in columns 1-6 and 




In the solvent dose-response assay, several organic solvents resulted in the formation of 
precipitates. At first, this was surprising because of the absence of compound. However, upon 
further investigation, it was discovered that BSA has low solubilities in most organic solvents 
that are not polar protic (Houen, 1996). This is fairly consistent with the amount of precipitate 
formation seen in the solvent dose-response assay. First, the amount of precipitate seen with 
triethylamine, cyclohexanone, benzylamine, and pyridine correlated with polarity. Triethylamine 
and cyclohexanone had approximately the least precipitate formation and are the most polar. 
Benzylamine resulted in more precipitation but is less polar since the amine group is connected 
to a nonpolar benzene ring. Pyridine, a polar aprotic solvent, resulted in the most precipitation. 
Interestingly, despite DMSO being polar aprotic, BSA was shown to have a relatively high 
solubility in DMSO (Houen, 1996) which is likely why no precipitate formed in the DMSO 
wells. However, acetone is a polar aprotic solvent which could explain the formation of 
precipitate in the 3:1 acetone-DMSO negative controls seen in the dose-response assays and the 
absence of precipitate in the DMSO only wells (Figure 12).  
The first compound dose-response assay procedure could not be completed as the first 
dilution resulted in a precipitate and the concentration in the remaining wells of the plate 
required that the previous concentration in the dilution series be precise and accurate. Because 
precipitation was observed, it was obvious that the concentration could not be precisely or 
accurately calculated. To better account for possible precipitation, the modification of the first 
assay to the second assay was to introduce new direct dilutions so that if precipitation were to 
occur in higher concentration wells, there would be other wells in the plate with concentrations 
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that would remain unaffected. Unfortunately, as mentioned above, precipitation was observed in 
all three initial dilution columns even in the second assay. 
Because none of the direct dilutions were successful in the second assay, and the 
literature EC50 values are sufficiently low, the final compound concentrations used in the third 
assay were decreased. Additionally, all of the compounds were prepared at 10 mM in DMSO 
prior to this assay. These changes led to the complete elimination of observable precipitation at 
the concentrations used.  However, the third assay showed only two compounds that resulted in 
activities greater than the DMSO control, but the differences were marginal compared to 
literature values for similar compounds (Figure 13).  
Considering the solubility issues in dissolving the compounds to make stock solutions in 
the first and second assays, the third assay procedure was modified to include the droplet 
method, similar to Chapleau et al. (2015), and was used for the fourth assay. Similar to the 
results of the third assay, the fourth assay yielded only marginal increases in activity above the 
DMSO control (Figure 14). Solubility was still a concern, so the incubation time was adjusted to 
one and two hours for the fifth assay to allow more time for the compounds to dissolve in case 
they were not completely solubilized. The A compounds were also included so that a direct 
comparison the Chapleau et al. (2015) experiments could be made. However, the data for the 
one-hour and two-hours incubations were still similar to the data from the fourth assay (Figures 
15-16). Considering that the incubation times for the Chapleau et al. (2015) and Katz et al. 
(2018) experiments were 10 minutes and 15 minutes respectively, a one-hour incubation should 
have been more than sufficient to produce the desired results. For this reason, only a one-hour 




For the sixth assay, the 200 mM sodium phosphate buffer was replaced with 40 mM 
sodium phosphate buffer to determine if the ionic strength of the solution impacted the 
interactions between the compounds and AChE. The fifth assay procedure was then repeated 
with this change to provide a direct comparison. However, the change in ionic strength did not 
appear to affect the results as the data from the fifth and sixth assays are nearly identical 
(Figures 15 & 17). 
The seventh assay was a repeat of the procedure for the fifth assay with different 
compounds and a slightly higher final concentration of AChE. Because it seemed that all of the 
compounds were completely solvated, other compounds were also tested to determine if they 
activated AChE. Unfortunately, this was not the case as all of the data associated with the 
compounds showed either inhibition similar to DMSO or inhibition greater than DMSO (Figure 
18-21).  The seventh assay procedure was then modified to include more compounds (15 
compounds plus the DMSO control vs the 7 compounds and DMSO control in the previous 
procedure) because the lower concentrations were not showing a significant difference in activity 
compared to DMSO. This allowed the compounds to be screened more quickly and efficiently. 
As mentioned above, the 300 uL Voyager pipette could no longer be used as the tips were 
depleted but instead had to be swapped with the 1250 uL pipette for the ninth through eleventh 
assays due to shipping delays related to the COVID-19 pandemic. This was not ideal as the 
volumes being pipetted were on the lower end of the 1250 uL pipette range. The change to the 
1250 uL pipette had a significant impact as the coefficient of variation (CV) for the ninth through 
eleventh assays was significantly greater (20-44%) compared to the previous assays (2-11%) 
which did not use the 1250 uL pipette. It is likely that this variation resulted because the volumes 
that were dispensed were on the lower end of the pipetting range for the 1250 uL pipette. The 
42 
 
error by the pipette would have then been exacerbated with each serial dilution (Hanson et al., 
2015). Further, despite the DMSO control being prepared in parallel with the compounds, the 
data for DMSO showed significant variation (Figures 26-33). Additionally, for the ninth assay, 
the concentration of AChE was increased. The thought was that at higher concentrations a 
greater fraction of the enzyme would be a dimer since AChE is known to dimerize 
(Sakayanathan et al., 2019). However, the results were largely the same from the previous assays 
meaning it is unclear whether the enzyme had a different globular form compared to the previous 
assays, or whether the compounds have the same effect on the monomer as the dimer. 
When the results obtained in the previous assays failed to reproduce those in the 
literature, the methods of Chapleau et al. (2015) and Katz et al. (2018) were analyzed again, and 
it was noted that BSA was not included in their procedures. Therefore, the ninth dose-response 
assay procedure was modified for the tenth assay to exclude BSA. In fact, one possible 
explanation for the discrepancy is that the compounds used by Chapleau et al. (2015) and Katz et 
al. (2018) did not actually activate AChE but rather stabilized AChE or refolded denatured or 
misfolded enzyme. BSA is known to stabilize AChE (Estrada-Mondaca & Fournier, 1998) and 
bind drugs with different structural motifs (Wani et al., 2021; Coura et al., 2021). The thought 
was that by excluding BSA, if the test compounds were stabilizing AChE, then this effect might 
not be as noticeable if BSA was stabilizing the positive control, or if BSA was binding the 
compounds leaving less compound available to bind to AChE. It is also possible that the 
mechanism by which BSA stabilizes AChE actually prevents the binding of the test compounds. 
In the controls for the Chapleau et al. (2015) and Katz et al. (2018) experiments, where the 
compounds were not present, the amount of remaining active AChE may have decreased while 
the AChE activity in the test solutions remained the same giving the appearance that the 
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compounds activated AChE. Alternatively, the compounds could have helped to refold denatured 
or misfolded enzyme, and despite the constant relative activity in the controls, the amount of 
activity in the test wells would have appeared to increase without actually activating AChE. 
However, neither the tenth assay nor the eleventh assay demonstrated results similar to either the 
Chapleau et al. (2015) or Katz et al. (2018) experiments (Figures 30-33).  Both assays excluded 
BSA, and the AChE for the eleventh assay was incubated at pH 6.0 and 37°C to test the refolding 
hypothesis. The activity of the incubated AChE versus nonincubated AChE did show a large 
difference suggesting that AChE was, in fact, denatured by the incubation process. 
The single-point tests excluded BSA but still resulted in precipitation for both 250 uM 
and 125 uM concentrations (Figures 36). If the solvent, DMSO, was precipitating AChE, similar 
to what was observed with BSA in the solvent-dose response assay, then it would be expected 
that precipitation should also occur in the DMSO control wells. However, no precipitation was 
observed in the DMSO control wells at either 2.5% or 1.25% DMSO. Additionally, the amount 
of precipitation across multiple assays positively correlated with the volume of test compound 
solution that was dispensed. The data from the single-point assays also did not show increases in 
activity comparable to that seen in the Chapleau et al. (2015) and Katz et al. (2018) experiments 
(Figures 34-35). 
Therefore, none of the results that were obtained are consistent with the results from the 
literature. Only a few compounds showed slight increases above the negative DMSO controls in 
the dose-response assays. In fact, some of the compounds demonstrated strong inhibition of 
AChE including the A compounds and the FDA-approved drugs. This is in sharp contrast to the 
multi-fold increases in activity that were reported previously. In particular, A3, A4, and A5 had 
EC50 values of less than 10 uM in human AChE (Chapleau et al., 2015) but were observed here 
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as either showing no change in activity or showing inhibition. Several explanations could be 
provided to give rationality to the discrepancies. 
One possible explanation for the discrepancies has to do with the specialized pipette tips 
that were being used during this project. The Low Retention pipette tips are made of a 
polypropylene blend that have heightened hydrophobic properties according to Integra’s website 
(https://www.integra-biosciences.com/united-states/en/pipette-tips). Although polypropylene is 
largely insoluble, the hydrophobic properties could affect nonpolar solvents and solutions. 
Integra has stated this may affect volume measurements of more nonpolar solutions, but there is 
also a possibility this could draw nonpolar solutes out of solution. Considering the compounds 
would not dissolve in more polar solvents (Table 1), these Low Retention tips may have 
interacted with the compounds. 
Another possible explanation for the discrepancy in results, is that the isoform and 
globular form of AChE that was used may have varied between experiments. The Chapleau et al. 
(2015) experiments used one of two forms of human AChE or mouse AChE. Interestingly, the 
mouse AChE showed greater affinity for the compounds than the human AChE (Chapleau et al., 
2015). Because the Katz et al. (2018) experiments used monomeric mouse AChE and the Radic 
AChE most closely resembles dimeric human AChE, it is possible the structural differences had 
an impact on the FDA-approved drugs activating AChE. Further, differences between the human 
AChE used in the Chapleau et al. (2015) experiments and the Radic isoform may also explain the 
differences with those results. However ultimately, the exact effect of structural variations 
between AChE isoforms on interactions with the test compounds is unknown. 
The last possible reason for the discrepancy in results that will be detailed here relates to 
the storage of the solubilized compounds. After each compound was prepared in solution, they 
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were stored at -80°C until they were ready for use, at which time they would be removed and 
allowed to slowly come to room temperature. Again, solubility was an issue so the compounds 
were mixed on either the Benchmark BV1010 Multi-tube Vortexer or an Eppendorf 
Thermomixer. The friction on the vortexer was sufficient to heat the tubes, but if the compounds 
were placed on the Thermomixer, the temperature was set to 37°C. With the large number of 
experiments performed, there is a possibility that the freeze/thaw cycles impacted the structural 
integrity of the compounds (Kozikowski et al., 2003). Further, the A compounds provided by Dr. 
McElroy were the result of decomposition from other compounds (McElroy, 2019), so it would 
be unsurprising if any of the A compounds or compounds 1-27 degraded in addition to any 
structural changes from the freeze/thaw cycles. 
Regardless of the cause, the inability to reproduce the literature values across multiple 
assays provides a valid reason to question the data from Chapleau et al. (2015) and Katz et al. 
(2018). With the current data, it is difficult to say whether the literature trends or the trends 
presented in this paper are more accurate. A fairly obvious step towards validating the data 
presented from this project would be to verify the structures of each compound by NMR. 
Additionally, as it is possible that the denaturing procedure did not truly mimic the denaturing or 
misfolding process that might have occurred in the AChE used in the Chapleau et al. (2015) and 
Katz et al. (2018) experiments, designing a set of procedures with varying conditions to denature 
or misfold the AChE could help elucidate the cause of the discrepancies. Lastly, a substrate 
concentration of 0.5 mM was used consistently with every assay that was performed in this 
project. However, Chapleau et al. (2015) and Katz et al. (2018) noted the use of a final 
concentration of ATC at 1 mM and 2 mM, respectively. Therefore, it may be worthwhile to 
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perform an assay procedure that includes varied ATC concentrations alongside the compounds to 
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